NZ598356A - Antigenic tau peptides and uses thereof - Google Patents

Antigenic tau peptides and uses thereof

Info

Publication number
NZ598356A
NZ598356A NZ598356A NZ59835610A NZ598356A NZ 598356 A NZ598356 A NZ 598356A NZ 598356 A NZ598356 A NZ 598356A NZ 59835610 A NZ59835610 A NZ 59835610A NZ 598356 A NZ598356 A NZ 598356A
Authority
NZ
New Zealand
Prior art keywords
seq
antigenic tau
tau peptides
antigenic
amino acid
Prior art date
Application number
NZ598356A
Other languages
English (en)
Inventor
Iii George Joseph Smith
Kenneth Nelson Wills
Jeff Xianchao Zhu
Original Assignee
Pfizer Vaccines Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Vaccines Llc filed Critical Pfizer Vaccines Llc
Priority to NZ618391A priority Critical patent/NZ618391A/en
Publication of NZ598356A publication Critical patent/NZ598356A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ598356A 2009-07-30 2010-07-20 Antigenic tau peptides and uses thereof NZ598356A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ618391A NZ618391A (en) 2009-07-30 2010-07-20 Antigenic tau peptides and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22986009P 2009-07-30 2009-07-30
PCT/IB2010/053313 WO2011013034A1 (en) 2009-07-30 2010-07-20 Antigenic tau peptides and uses thereof

Publications (1)

Publication Number Publication Date
NZ598356A true NZ598356A (en) 2014-06-27

Family

ID=42941871

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ598356A NZ598356A (en) 2009-07-30 2010-07-20 Antigenic tau peptides and uses thereof
NZ618391A NZ618391A (en) 2009-07-30 2010-07-20 Antigenic tau peptides and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ618391A NZ618391A (en) 2009-07-30 2010-07-20 Antigenic tau peptides and uses thereof

Country Status (17)

Country Link
US (1) US20110177109A1 (enEXAMPLES)
EP (1) EP2459214A1 (enEXAMPLES)
JP (1) JP2013500326A (enEXAMPLES)
KR (2) KR20120049900A (enEXAMPLES)
CN (1) CN102596236B (enEXAMPLES)
AR (1) AR078085A1 (enEXAMPLES)
AU (1) AU2010277254B2 (enEXAMPLES)
CA (1) CA2768346A1 (enEXAMPLES)
CO (1) CO6612199A2 (enEXAMPLES)
IN (1) IN2012DN00446A (enEXAMPLES)
MX (1) MX2012001194A (enEXAMPLES)
NZ (2) NZ598356A (enEXAMPLES)
PE (1) PE20120817A1 (enEXAMPLES)
RU (2) RU2518291C2 (enEXAMPLES)
SG (1) SG177637A1 (enEXAMPLES)
TW (2) TW201436804A (enEXAMPLES)
WO (1) WO2011013034A1 (enEXAMPLES)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011006088A (es) 2008-12-09 2011-06-21 Coley Pharm Group Inc Oligonucleotidos inmunoestimuladores.
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
EP3329932A1 (en) 2009-06-10 2018-06-06 New York University Immunological targeting of pathological tau proteins
AU2013205313B2 (en) * 2010-10-07 2016-05-19 Ac Immune S.A. Phosphospecific antibodies recognising tau
MX338421B (es) 2010-10-07 2016-04-15 Ac Immune Sa Anticuerpos fosfoespecificos que reconocen la proteina tau.
US20120244174A1 (en) 2011-01-31 2012-09-27 Intellect Neurosciences Inc. Treatment of tauopathies
MX339762B (es) 2011-09-28 2016-05-27 Univ Autonoma Del Estado De Morelos Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen.
WO2013050567A1 (en) 2011-10-07 2013-04-11 Ac Immune S.A. Phosphospecific antibodies recognising tau
KR102132041B1 (ko) 2012-04-05 2020-07-09 에이씨 이뮨 에스.에이. 인간화된 타우 항체
SG10201708959WA (en) * 2012-07-03 2017-11-29 Univ Washington Antibodies to tau
EA035976B1 (ru) 2012-08-16 2020-09-08 АйПИЕРИАН, ИНК. Анти-tau антитела для лечения таупатий
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
RU2661111C2 (ru) 2013-03-15 2018-07-11 Ац Иммуне С.А. Антитела к тау и способы применения
US10195257B2 (en) * 2013-07-28 2019-02-05 Qantu Therapeutics, Inc. Vaccine formulations comprising quillaja desacylsaponins and beta amyloid peptides or tau protein to induce a Th2 immune response
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
TWI664190B (zh) 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗－ｔａｕ抗體
US10132818B2 (en) 2014-07-08 2018-11-20 New York University Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
WO2016154522A1 (en) * 2015-03-25 2016-09-29 Stc. Unm Immunotherapy compositions and methods for treatment of tauopathy and transgenic mouse
TN2017000543A1 (en) 2015-07-06 2019-04-12 Ucb Biopharma Sprl Tau-binding antibodies
US10988528B2 (en) 2015-08-13 2021-04-27 New York University Antibody-based molecules specific for the truncated ASP421 epitope of Tau and their uses in the diagnosis and treatment of tauopathy
US11884707B2 (en) 2016-09-29 2024-01-30 Regeneron Pharmaceuticals, Inc. Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same
GB201700487D0 (en) 2017-01-11 2017-02-22 Hermon-Taylor John Diagnostic
EA202091012A1 (ru) * 2017-10-25 2020-08-27 Янссен Фармасьютикалз, Инк. Композиции фосфорилированных тау-пептидов и их применения
CN119409835A (zh) * 2017-10-27 2025-02-11 联脑科学公司 Tau肽免疫原构建体
CN109870581B (zh) * 2017-12-04 2021-05-04 厦门万泰凯瑞生物技术有限公司 一种定量检测HBsAg的试剂盒及方法
CN108314737B (zh) * 2018-01-25 2021-03-16 中国科学院过程工程研究所 一种重组蛋白及其制备方法和应用
CN110548135B (zh) * 2018-05-31 2023-06-06 长春百克生物科技股份公司 磷酸化多肽抗原疫苗及其制备方法和应用
GB201811382D0 (en) 2018-07-11 2018-08-29 Taylor John Hermon Vaccine
AU2019356804B2 (en) 2018-10-07 2025-05-29 Promis Neurosciences, Inc. Conformation-specific epitopes in alpha-synuclein, antibodies thereto and methods related thereof
CA3129252A1 (en) 2019-02-08 2020-08-13 Ac Immune S.A. Method of safe administration of phosphorylated tau peptide vaccine
CN119954947A (zh) * 2019-02-08 2025-05-09 普罗塞纳生物科学有限公司 识别Tau的抗体
WO2020186091A1 (en) * 2019-03-12 2020-09-17 Indi Molecular, Inc. Cross-linked epitopes and methods of use thereof
CA3135170A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
US12201679B2 (en) 2019-04-05 2025-01-21 Institute For Systems Biology Epitope-targeted peptide immunostimulants
AU2020262899A1 (en) 2019-04-24 2021-11-18 Ac Immune S.A. Heterologous administration of tau vaccines
US12216122B2 (en) 2019-05-20 2025-02-04 Regeneron Pharmaceuticals, Inc. Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (IDO1)
EP3976793A4 (en) * 2019-05-27 2023-06-21 The University of British Columbia CONFORMATION SPECIFIC EPITOPES IN A TAU PROTEIN, ANTIBODIES THEREOF AND METHODS THEREOF
GB2585252A (en) * 2019-07-05 2021-01-06 Gen2 Neuroscience Ltd Tau epitope and binding molecules
US12209142B2 (en) 2020-05-29 2025-01-28 Institute For Systems Biology SARS-CoV-2 epitope-targeted peptide immunostimulants
CA3188458A1 (en) * 2020-08-07 2022-02-10 Robin Barbour Tau vaccine for the treatment of alzheimer's disease
US20230310561A1 (en) * 2020-09-08 2023-10-05 Osaka University Immunogenic composition targeting phosphorylated tau protein
IL311337A (en) * 2021-09-08 2024-05-01 Joint Stock Company «Biocad» A bispecific antibody that includes a heterogeneous dimer based on MHC proteins
MX2024003775A (es) * 2021-09-29 2024-04-11 Janssen Pharmaceuticals Inc Metodo de administracion segura del conjugado de fosfopeptido de tau.
CN115894659B (zh) * 2022-10-19 2023-11-10 上海优宁维生物科技股份有限公司 微管相关蛋白Tau抗原及其制备方法和应用

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
EP0092574B1 (en) 1981-10-23 1992-04-29 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and methods of making same
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
DE3525624A1 (de) 1985-07-18 1987-01-22 Celamerck Gmbh & Co Kg Insektizid wirksames mittel zur bekaempfung von textilschaedlingen
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
NZ235315A (en) 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
WO1992011291A1 (en) 1990-12-20 1992-07-09 Smithkline Beecham Biologicals (S.A.) Vaccines based on hepatitis b surface antigen
US7408027B1 (en) * 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
ES2136654T3 (es) * 1991-12-06 1999-12-01 Max Planck Gesellschaft Herramientas para el diagnostico y tratamiento de la enfermedad de alzheimer.
EP0544942A1 (en) * 1991-12-06 1993-06-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel tools for the diagnosis and treatment of Alzheimer disease
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
ES2162139T5 (es) 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
DE4321946A1 (de) 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5658738A (en) 1994-05-31 1997-08-19 Becton Dickinson And Company Bi-directional oligonucleotides that bind thrombin
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1167377B2 (en) 1994-07-15 2012-08-08 University of Iowa Research Foundation Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
CN1185811A (zh) 1995-03-31 1998-06-24 H·沃尔夫 依赖于逆转录病毒样颗粒的抗原呈递系统
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
WO1997034145A1 (fr) * 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
WO1998022120A1 (en) * 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
US6214806B1 (en) 1997-02-28 2001-04-10 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders
PT1005368E (pt) 1997-03-10 2009-11-19 Coley Pharm Gmbh Utilização de ácidos nucleicos contendo dinucleótidos cpg não metilados em combinação com alúmen como adjuvante
CA2301575C (en) 1997-05-20 2003-12-23 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
JP4280309B2 (ja) 1997-06-06 2009-06-17 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア Ｄｎａ免疫刺激配列活性の阻害剤
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
JP4480268B2 (ja) 1998-02-12 2010-06-16 イミューン コンプレックス コーポレイション 戦略的修飾されたｂ型肝炎コアタンパク質及びそれらの誘導体
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
NZ506603A (en) 1998-04-09 2002-10-25 Smithkline Beecham Biolog S Adjuvant compositions comprising polyoxyethylene ether or polyoxyethylene ester
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
SI1126876T1 (sl) 1998-10-16 2007-08-31 Glaxosmithkline Biolog Sa Adjuvantni sistemi in vakcine
DE69929232T2 (de) 1998-10-21 2006-08-31 The United States Government As Represented By The Department Of Health And Human Services Virusähnliche partikel zur induktion von autoantikörpern
CA2349505A1 (en) 1998-11-05 2000-05-11 Powderject Vaccines, Inc. Nucleic acid constructs for genetic immunization
AU768807B2 (en) 1998-11-30 2004-01-08 Cytos Biotechnology Ag Ordered molecular presentation of antigens, method of preparation and use
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
US7776343B1 (en) 1999-02-17 2010-08-17 Csl Limited Immunogenic complexes and methods relating thereto
BRPI0009163B8 (pt) 1999-03-19 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica e vacina que a compreende
AU764969B2 (en) 1999-04-19 2003-09-04 Smithkline Beecham Biologicals (Sa) Vaccines
EP1221971A2 (en) 1999-09-24 2002-07-17 SmithKline Beecham Biologics SA Use of the combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
KR20020048942A (ko) 1999-09-24 2002-06-24 장 스테판느 폴리옥시에틸렌 알킬 에테르 또는 에스테르 및 하나이상의 비이온성 계면활성제를 포함하는 애쥬번트
ATE336502T1 (de) 2000-04-07 2006-09-15 Univ Leeds Hepatitis b kernprotein fusionsproteine
AU2001252458A1 (en) 2000-05-05 2001-11-20 Martin Bachmann Molecular antigen arrays and vaccines
ES2260235T3 (es) 2000-06-22 2006-11-01 Ucb Pharma Limited Modificacion del antigeno "core" de la hepatitis b.
AU2001269272A1 (en) 2000-07-15 2002-01-30 Lighthouse Display International Limited Shelf edge display fittings
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
WO2003102165A2 (en) 2002-02-21 2003-12-11 Apovia, Inc. IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE
AU2002339224B2 (en) 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
AU2002347404A1 (en) 2001-09-14 2003-04-01 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
US20040176283A1 (en) 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
GB0209878D0 (en) 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
CN102061288A (zh) 2002-07-17 2011-05-18 希托斯生物技术股份公司 使用衍生自ap205外壳蛋白的病毒样颗粒的分子抗原阵列
ATE506964T1 (de) * 2002-07-19 2011-05-15 Cytos Biotechnology Ag Impfstoffzusammensetzungen enthaltende amyloid beta 1-6 antigenarrays
AU2003300841B2 (en) 2002-12-10 2008-03-20 Lorantis Ltd. Stabilized immunogenic HBc chimer particles
HUE026000T2 (en) * 2003-12-17 2016-04-28 Wyeth Llc Immunogenic peptide-bearing conjugates and methods for their preparation
EP1776105A2 (en) 2004-07-18 2007-04-25 Coley Pharmaceutical Group, Ltd Methods and compositions for inducing innate immune responses
US20060287263A1 (en) 2004-07-18 2006-12-21 Csl Limited Methods and compositions for inducing antigen-specific immune responses
KR20070084170A (ko) * 2004-10-13 2007-08-24 아블린쓰 엔.브이. 알쯔하이머병 등의 퇴행성 신경 질환의 치료 및 진단을위한 단일 도메인 카멜리드 항-아밀로이드 베타 항체 및이를 포함하는 폴리펩타이드
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
DE602006015421D1 (de) * 2006-04-13 2010-08-26 Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh HER-2/neu Multipeptidimpfstoff
US20080166785A1 (en) 2006-08-16 2008-07-10 Monica Sala-Schaeffer Polynucleotides allowing the expression and secretion of recombinant HBsAg virus-like particles containing a foreign peptide, their production and use
EP3329932A1 (en) * 2009-06-10 2018-06-06 New York University Immunological targeting of pathological tau proteins
FR3058624B1 (fr) 2016-11-15 2018-12-07 L'oreal Brosse pour l'application d'un produit sur les cils et/ou les sourcils

Also Published As

Publication number Publication date
AU2010277254A1 (en) 2012-02-09
AR078085A1 (es) 2011-10-12
RU2518291C2 (ru) 2014-06-10
JP2013500326A (ja) 2013-01-07
CN102596236A (zh) 2012-07-18
RU2012102701A (ru) 2013-09-10
IN2012DN00446A (enEXAMPLES) 2015-05-15
AU2010277254B2 (en) 2015-05-07
RU2014112002A (ru) 2015-10-10
CO6612199A2 (es) 2013-02-01
CA2768346A1 (en) 2011-02-03
CN102596236B (zh) 2015-06-24
KR20120049900A (ko) 2012-05-17
US20110177109A1 (en) 2011-07-21
TWI461209B (zh) 2014-11-21
PE20120817A1 (es) 2012-07-07
SG177637A1 (en) 2012-03-29
KR20130127547A (ko) 2013-11-22
TW201436804A (zh) 2014-10-01
WO2011013034A1 (en) 2011-02-03
TW201106968A (en) 2011-03-01
MX2012001194A (es) 2012-03-07
WO2011013034A4 (en) 2011-04-28
EP2459214A1 (en) 2012-06-06
NZ618391A (en) 2015-07-31

Similar Documents

Publication Publication Date Title
NZ598356A (en) Antigenic tau peptides and uses thereof
NZ600731A (en) Oxyntomodulin peptide analogue
MX2011011960A (es) Peptidos penetradores de celulas.
NZ600732A (en) Oxyntomodulin peptide analogue
NZ602845A (en) Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof
NZ620441A (en) Pcsk9 vaccine
MX347200B (es) Péptidos procoagulantes y sus derivados, y usos para estos.
MX340014B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012008998A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
NZ609216A (en) Anticancer fusion protein
WO2012051498A3 (en) Antibodies that bind amyloid oligomers
NZ601488A (en) Immunogenic proteins and compositions
NZ598932A (en) Identification of antigenic peptides from multiple myeloma cells
NZ609916A (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
NZ586074A (en) LCLRP peptides, constructs and uses thereof
NZ703514A (en) Fviii peptides for immune tolerance induction and immunodiagnostics
WO2008113536A8 (en) Neurotrophic peptides
AR083766A1 (es) Peptido inmunogenico
NZ592461A (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same
NZ591133A (en) Novel melanoma antigen peptide and uses thereof
WO2012031103A3 (en) Inhibitors of bcl-2
GB201018125D0 (en) Peptide
NZ603379A (en) Ect2 peptides and vaccines including the same

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 20 JUL 2017 BY THOMSON REUTERS

Effective date: 20141120

LAPS Patent lapsed